STOCK TITAN
  1. Home
  2. Sec-filings
  3. pcvx
  4. [Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte (NASDAQ: PCVX) director receives RSUs and stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. director Heath Lukatch reported equity compensation awards rather than open-market trades. He received 2,265 shares of Common Stock through restricted stock units, with each RSU representing one share, and 11,389 stock options to buy Common Stock at an exercise price of $49.56 per share.

The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service and possible acceleration. The stock options vest monthly on the same schedule and expire on June 15, 2036. Following the RSU grant, Lukatch directly holds 19,481 shares of Common Stock.

Positive

  • None.

Negative

  • None.
Insider Lukatch Heath
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 11,389 $0.00 --
Grant/Award Common Stock 2,265 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 11,389 shares (Direct, null); Common Stock — 19,481 shares (Direct, null)
Footnotes (1)
  1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
RSU grant 2,265 shares Restricted stock units awarded to director on June 15, 2026
Stock options granted 11,389 options Stock Option (right to buy) awarded on June 15, 2026
Option exercise price <money>$49.56</money> per share Exercise price for 11,389 stock options
Option expiration <date>June 15, 2036</date> Expiration date of stock option grant
Shares held after grant 19,481 shares Total Common Stock directly owned after RSU award
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 49.5600."
continuous service financial
"subject to the Reporting Person's continuous service through such date."
annual meeting of stockholders financial
"the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lukatch Heath
(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026A2,265(1)A$019,481D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$49.5606/15/2026A11,389 (2)06/15/2036Common Stock11,389$011,389D
Explanation of Responses:
1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Remarks:
Heath Lukatch, by /s/ Peter N. Efremenko, Attorney-In-Fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Vaxcyte (PCVX) director Heath Lukatch receive in this Form 4 filing?

Heath Lukatch received an equity compensation package, including 2,265 restricted stock units and 11,389 stock options. These awards increase his potential ownership but do not involve any open-market purchases or sales of Vaxcyte Common Stock.

How many Vaxcyte (PCVX) shares are covered by Heath Lukatch’s RSU grant?

The RSU grant covers 2,265 shares of Vaxcyte Common Stock. Each restricted stock unit represents the right to receive one share, subject to vesting conditions tied to time and continued service with the company.

What are the key terms of Heath Lukatch’s Vaxcyte (PCVX) stock options?

Lukatch received 11,389 stock options to buy Vaxcyte Common Stock at an exercise price of $49.56 per share. The options vest monthly and expire on June 15, 2036, provided he continues serving the company.

When do Heath Lukatch’s new Vaxcyte (PCVX) RSUs fully vest?

The RSUs fully vest on the earlier of June 15, 2027 or the day before Vaxcyte’s next annual stockholder meeting. Vesting requires Heath Lukatch to maintain continuous service with the company through that date, subject to any permitted acceleration.

How many Vaxcyte (PCVX) Common Stock shares does Heath Lukatch hold after this grant?

After the RSU grant, Heath Lukatch directly holds 19,481 shares of Vaxcyte Common Stock. This figure reflects his reported direct ownership position following the award and does not include unexercised options or unvested RSUs.

Is Heath Lukatch’s Form 4 for Vaxcyte (PCVX) a market buy or sell?

No, this filing reports equity compensation awards, not market trades. The transactions are coded as “A” grants, meaning he acquired RSUs and stock options from Vaxcyte as compensation, without paying a purchase price in the open market.